Novo Nordisk Stock Tumbles as CEO Defends Diversification — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Novo Nordisk CEO defended the company's diversification strategy and signaled interest in M&A deals beyond its obesity franchise during a strategy update.
- Novo Nordisk shares slumped as management faced investor grilling on pricing, acquisition strategy, and the company's pivot beyond Wegovy.
- Investors pushed back on Novo's consumer health plans and blockbuster pipeline ambitions, leaving the stock to fall after the drugmaker unveiled its broader strategic vision.
Why it matters: Novo Nordisk's push to diversify beyond Wegovy met investor pushback on pricing and M&A, dragging shares lower and showing that the drugmaker must now prove growth without leaning entirely on its obesity franchise.
Ask SkimNews
